Overview

Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

Status:
Completed
Trial end date:
2019-06-06
Target enrollment:
Participant gender:
Summary
This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.
Phase:
Phase 3
Details
Lead Sponsor:
Allergan
Treatments:
Ranibizumab